SEC Comment Letter for Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248) (CMMB) — Aug 29, 2024
Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248)
Date: Aug. 29, 2024 · CIK: 0001534248 · Accession: 0000000000-24-009837
AI Filing Summary & Sentiment
File numbers found in text: 333-281750
Letter
August 29, 2024 Adi Mor Chief Executive Officer Chemomab Therapeutics Ltd. Kiryat Atidim, Building 7 Tel Aviv, Israel 6158002 Re:Chemomab Therapeutics Ltd. Registration Statement on Form F-3 Filed August 23, 2024 File No. 333-281750 Dear Adi Mor: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Matthew Randolph
Show Raw Text
August 29, 2024
Adi Mor
Chief Executive Officer
Chemomab Therapeutics Ltd.
Kiryat Atidim, Building 7
Tel Aviv, Israel 6158002
Re:Chemomab Therapeutics Ltd.
Registration Statement on Form F-3
Filed August 23, 2024
File No. 333-281750
Dear Adi Mor:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Matthew Randolph